Group 1 - The core viewpoint of the articles highlights the performance and valuation of Kangdelai, a company in the medical device industry, which has a current PE ratio of 15.61, significantly lower than the industry average of 50.63 [1][2] - As of the first quarter of 2025, Kangdelai reported a revenue of 548 million yuan, a year-on-year decrease of 3.82%, and a net profit of 60.70 million yuan, with a slight increase of 0.28% [1] - The company has a total market capitalization of 3.363 billion yuan, ranking 37th in the medical device industry based on PE ratio [1][2] Group 2 - Kangdelai's main business includes the research, production, sales, and service of medical devices such as puncture needles and infusion devices [1] - The company has established research centers, including a municipal technology center in Shanghai and a provincial puncture medical device research institute in Zhejiang [1] - The average PE ratio for the medical device industry is 50.63, with a median of 37.15, indicating that Kangdelai is undervalued compared to its peers [2]

6月24日，康德莱今日收盘7.5元，上涨2.46%，滚动市盈率PE（当前股价与前四季度每股收益总和的比 值）达到15.20倍，总市值32.76亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均49.12倍，行业中值36.07倍，康德莱排名 第35位。 股东方面，截至2025年3月31日，康德莱股东户数25817户，较上次减少822户，户均持股市值35.28万 元，户均持股数量2.76万股。 上海康德莱企业发展集团股份有限公司的主营业务是医用穿刺针、医用输注器械等医疗器械的研发、生 产、销售和服务。公司的主要产品是穿刺护理类、输液导管类、留置输注类、穿刺介入类、医疗美容 类、药包材类、动物医疗类、胰岛素给药类、标本采集类、有源医疗器械类。公司总部的研发机构为上 海市级企业技术中心，子公司浙江康德莱设立了省级穿刺医疗器械研究院，子公司广东医械集团的研发 中心被认定为广东省穿刺类医疗器械工程技术研究中心及珠海市企业技术中心。 最新一期业绩显示，2025年一季报，公司实现营业收入5.48亿元，同比-3.82%；净利润6070.42万元，同 比0.28%，销售毛利率32.02%。 序号股票简称PE(TTM) ...

最新一期业绩显示，2025年一季报，公司实现营业收入5.48亿元，同比-3.82%；净利润6070.42万元，同 比0.28%，销售毛利率32.02%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)35康德莱15.1815.191.2632.72亿行业平均 49.6447.924.61106.85亿行业中值36.3637.152.4549.28亿1天益医疗-1776.29-3042.591.9022.64亿2澳华内 镜-644.66323.335.1667.94亿3诺唯赞-407.58-482.062.2487.22亿4爱朋医疗-359.62273.204.3329.51亿5博晖 创新-330.17523.933.5248.44亿6奥精医疗-139.08-203.851.8325.81亿7硕世生物-137.56-2010.081.2340.24亿 8睿昂基因-102.37-84.041.4513.25亿9康泰医学-89.13-75.303.1858.66亿10中红医疗-72.45-57.790.9250.35亿 11华大智造-55.85-49.563.85297.77亿 来源：金融界 5月29日，康 ...

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Kangdai, a company in the medical device industry, which is currently facing challenges with a lower-than-average PE ratio compared to its peers [1][2] - As of May 22, Kangdai's closing price was 7.35 yuan, with a rolling PE ratio of 14.90 times and a total market capitalization of 3.21 billion yuan [1] - The average PE ratio for the medical device industry is 48.71 times, with a median of 35.37 times, placing Kangdai at the 34th position within the industry [1][2] Group 2 - As of the first quarter of 2025, seven institutions hold shares in Kangdai, with a total of 197.34 million shares valued at 1.446 billion yuan [1] - Kangdai's main business includes the research, production, sales, and service of medical devices such as puncture needles and infusion devices, with a diverse product range [1] - The latest financial report for the first quarter of 2025 shows Kangdai achieved a revenue of 548 million yuan, a year-on-year decrease of 3.82%, and a net profit of 60.70 million yuan, a year-on-year increase of 0.28%, with a gross profit margin of 32.02% [1]

5月20日，康德莱今日收盘7.46元，上涨1.08%，滚动市盈率PE（当前股价与前四季度每股收益总和的比 值）达到15.12倍，创30天以来新低，总市值32.58亿元。 最新一期业绩显示，2025年一季报，公司实现营业收入5.48亿元，同比-3.82%；净利润6070.42万元，同 比0.28%，销售毛利率32.02%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)35康德莱15.1215.131.2532.58亿行业平均 49.5147.734.57106.36亿行业中值36.1737.202.5148.58亿1天益医疗-1784.15-3056.061.9022.74亿2澳华内 镜-619.74310.834.9665.31亿3诺唯赞-415.76-491.732.2888.97亿4爱朋医疗-370.37281.374.4630.39亿5博晖 创新-330.72524.813.5348.52亿6硕世生物-137.27-2005.841.2340.15亿7奥精医疗-130.15-190.761.7224.15亿 8睿昂基因-105.86-86.911.5013.70亿9康泰医学-86.99-73. ...